JNJ240628C130000
- 18.72
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.
According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.
Johnson & Johnson Receives Canadian Approval for Rybrevant in First-line NSCLC
U.S. Indicated Dividend Payments Rose in Q2 Led by Alphabet's Initiation
Top High Quality Stocks That Pay Dividends - UBS
Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval
By Michael Susin Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditio
Express News | Health Canada Authorizes Rybrevant® (Amivantamab) in Combination With Carboplatin and Pemetrexed as the Only Targeted First-Line Treatment Approved for Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations
China International Capital Corporation: Colored contact lenses promote demand upgrade, and manufacturing business enters the golden development period.
Terminal demand upgrades, technological innovation, and changes in the market landscape will drive rapid development in the domestic industry chain. Contact lenses and colored contact lenses will usher in new development opportunities and are expected to continue to maintain a strong growth trend in the next few years.
Express News | Johnson & Johnson has received approval from the US Food and Drug Administration and the European Commission for SIRTURO (bedaquiline), a pharmaceutical.
Express News | Johnson & Johnson Receives Approval From U.S. FDA and European Commission for Sirturo® (Bedaquiline)
JNJ Should Rally Soon or See 3 Swings Higher at Least
Johnson & Johnson (JNJ) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue.
J&J Says Carvykti Beat Standard Drugs in Late-stage Blood Cancer Trial
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise
Johnson & Johnson (JNJ) said on Tuesday interim analysis of the Phase 3 study of its experimental therapy, Carvykti, to treat certain patients with a type of blood cancer showed a statistically signif
Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival
Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Cl
Express News | J&J -Safety Data Were Consistent With Approved Label
Express News | Carvykti® (Ciltacabtagene Autoleucel) Achieved Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Landmark Cartitude-4 Study
With 71% Ownership, Johnson & Johnson (NYSE:JNJ) Boasts of Strong Institutional Backing
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their trading actions 42% of the business is held by the top 25 shareholders Analys
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Broad stock market indexes like the S&P 500 hit all-time highs in the first half of 2024.The Dow Jones Industrial Average also hit all-time highs, but saw a smaller return in the first half of the yea
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive in
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price target.
Johnson & Johnson Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 46.83% Cantor Fitzgerald $215 → $215 Reiterates Overweight → Overweight 06/25/2024 46.83% Canto